Response by Bonaca and Sabatine to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)”
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2018 |
| Reihe/Periodikum: | Circulation ; volume 138, issue 2, page 222-223 ; ISSN 0009-7322 1524-4539 |
| Verlag/Hrsg.: |
Ovid Technologies (Wolters Kluwer Health)
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29683628 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1161/circulationaha.118.034864 |
